Rallybio(RLYB)
NEW HAVEN, CTBiotechnology
Focus: Rallybio is a public-stage oncology-focused biotechnology company headquartered in New Haven, CT, currently undergoing strategic restructuring following a merger with Avenzo Therapeutics. The company operates with minimal commercial revenue and is primarily R&D-driven.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Rallybio
AI assessmentNot HiringNo open roles listed right now. Follow Rallybio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rallybio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$636K
Pipeline & Clinical Trials
Clinical data collection
Fetal and Neonatal Alloimmune ThrombocytopeniaClinical Trials (1)
NCT05345561Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
N/AHelp build intelligence for Rallybio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.